Analysis of hematological parameters as prognostic markers for toxicity and survival of (223)Radium treatment

(223)Radium ((223)Ra) has emerged as treatment prolonging survival in patients with metastatic castration-resistant prostate cancer (CRPC). As (223)Ra can cause hematotoxicity (HT), pre-existing hematopoiesis might influence the efficacy of (223)Ra and the rate of hematotoxicity, but as to our knowl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Leisser, Asha, Nejabat, Marzieh, Hartenbach, Markus, Agha Mohammadi Sareshgi, Reza, Shariat, Shahrokh, Kramer, Gero, Krainer, Michael, Hacker, Marcus, Haug, Alexander R.
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5882327/
https://ncbi.nlm.nih.gov/pubmed/29662636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24610
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares